

Ref. By : DR. BHATT NEELIMA

Address :

33 Years / Male Reg No. : 20736

Reg. Date : 21/08/2022 10:09AM

Collected At : MedZone Center

INVESTIGATION REPORT

CLINICAL BIOCHEMISTRY

TEST	<u>RESULT</u>	<u>UNIT</u>	BIOLOGICAL REF RANGE	TEST METHOD
CRP (C-Reactive Protein Quant	<u>titative)</u>			
Sample Type	: SERUM			
CRP (C-Reactive Protein Quantitative)	: 9.24	mg/L	Upto 6	Nephelometry (
		•		Fully Automated
				Quantitative
				Analyz

C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation (an acute-phase protein). Its physiological role is to bind to phosphocholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via c1q. CRP is synthesized by the liver in response to factors released by fat cells (adipocytes). It is a member of the pentraxin family of proteins. It is not related to C-peptide or protein C. CRP is used mainly as a marker of inflammation. Apart from liver failure, there are few known factors that interfere with CRP production. Measuring and charting CRP values can prove useful in determining disease progress or the effectiveness of treatments. CRP is therefore a test of value in medicine, reflecting the presence and intensity of inflammation, although an elevation in C-reactive protein is not the telltale diagnostic sign of any one condition.

METHOD : Turbidometry

INSTRUMENT: A-25 Biosystem (Spain) Fully Automated Chemistry Analyser



Ref. By : DR. BHATT NEELIMA

Address :

33 Years / Male Reg No. : 20736

Reg. Date : 21/08/2022 10:09AM Collected At : MedZone Center

INVESTIGATION REPORT

CLINICAL BIOCHEMISTRY

<u>TEST</u>	<u>RESULT</u>	<u>UNIT</u>	BIOLOGICAL REF RANGE	TEST METHOD
Glycosylated Hemoglobin (GHb/HB	A1c)			
Sample Type	: WB - EDTA			
Glycosylated Hemoglobin (GHb/HBA1c)	: 5.1	%	4.8 - 6.0 : Non Diabetic 6.0 - 7.0 : Good Control 7.0 - 8.0 : Weak Control More than 8 : Poor Control	Biorad D10 HPLC

Glycosylated hemoglobin (*hemoglobin A1c, HbA1c, A1C, or Hb1c*; sometimes also *HbA1c*) is a form of hemoglobin used primarily to identify the average plasma glucose concentration over prolonged periods of time. It is formed in a non-enzymatic pathway by hemoglobin's normal exposure to high plasma levels of glucose. Glycation of hemoglobin has been associated with cardiovascular disease, nephropathy and retinopathy in diabetes mellitus. Monitoring the HbA1c in type-1 diabetic patients may improve treatment. HbA1c is a weighted average of blood glucose levels during the preceding 120 days, which is the average life span of red blood cells. A large change in mean blood glucose can increase HbA1c levels within 1-2 weeks. Sudden changes in HbA1c may occur because recent changes in blood glucose levels contribute relatively more to the final HbA1c levels than earlier events. For instance, mean blood glucose levels in the 30 days immediately preceding blood sampling contribute 50% to the HbA1c level, whereas glucose levels in the preceding 90-120 day period contribute only 10%. Thus, it does not take 120 days to detect a clinically meaningful change in HbA1c following a significant change in mean plasma glucose level.

METHOD: Ion Exchange Chromatography High performance liquid chromatography(HPLC)

: 21/08/2022 10:09AM

: 21/08/2022 10:11AM

: 21/08/2022 02:58PM

INSTRUMENT: D -10 Bio-Rad Laboratories;FRANCE

Sample Registered On

Sample Received On Report Released On

Sample Barcode :

--- End Of Report ---

Dr. VANDANA CHANDANI

Checked By:tulesh

Page 2 of 7



Ref. By : DR. BHATT NEELIMA

Address :

33 Years / Male

MaleReg No. : 20736Reg. Date: 21/08/2022 10:09AMCollected At: MedZone Center

INVESTIGATION REPORT

CLINICAL PATHOLOGY

TEST

RESULT UNIT

TEST METHOD



PH-09228333 MOBILE-9300888178

NAME : MR MOHAN THAKUR

Ref. By : DR. BHATT NEELIMA

Address :

33 Years / Male Reg No. : 20736

Reg. Date : 21/08/2022 10:09AM

Collected At : MedZone Center

INVESTIGATION REPORT

CLINICAL PATHOLOGY

<u>TEST</u>	<u>RESULT</u>	<u>UNIT</u>	TEST METHOD			
<u>Montoux test</u>						
Sample Type	: Select Sam	nple Type				
Method	: DONE BY MA	: DONE BY MANTOUX METHOD.10/5 TU OF PPD INJECTED				
	INTRADERMA	ALLY INTO VENTRAL ASPECT O	F LEFT FORE-ARM 3cm			
	BELOW THE E	ELBOW JOINT.				
P.P.D injected	: 5tu					
Induration	: READ AFTER	48 HRS.INDURATION OF 20 M	M BY 18 MM IS NOTED.			
Interpretation	: TEST IS POSIT	IVE				



ADVANCE DIAGNOSTICS CENTRE

C1-C2/17A, NEAR NIHARIKA TALKIES KORBA- 495677 PH-09228333 MOBILE-9300888178

NAME : MR MOHAN THAKUR

Ref. By : DR. BHATT NEELIMA

Address :

33 Years / Male

MaleReg No. : 20736Reg. Date: 21/08/2022 10:09AMCollected At: MedZone Center

INVESTIGATION REPORT

CLINICAL PATHOLOGY

<u>TEST</u>	<u>RESULT</u>	UNIT	TEST METHOD
How Are TST Reactions Interpreted?			
Skin test interpretation depends on two factors:			
Measurement in millimeters of the induration			
·Person's risk of being infected with TB and of p	rogression to disea	se if infected	
Classification of the Tuberculin Skin Test Reaction	n		
An induration of 5 or more millimeters is conside	ered positive in		
-HIV-infected persons			
-A recent contact of a person with TB disease			
-Persons with fibrotic changes on chest radiograp	h consistent with p	rior TB	
-Patients with organ transplants			
-Persons who are immunosuppressed for other re	easons (e.g., taking	the equivalent of >15 mg/day of	
prednisone for 1 month or longer, taking TNF- α a	intagonists)		
An induration of 10 or more millimeters is consid	dered positive in		
-Recent immigrants (< 5 years) from high-prevale	nce countries		
-Injection drug users			
-Residents and employees of high-risk congregate	e settings		
-Mycobacteriology laboratory personnel			
-Persons with clinical conditions that place them	at high risk		
-Children < 4 years of age			
- Infants, children, and adolescents exposed to ac	Jults in high-risk cat	egories	
An induration of 15 or more millimeters is consid	dered positive in an	y person, including persons with no known	
risk factors for TB. However, targeted skin testing	; programs should c	only be conducted among high-risk groups.	
What Are False-Positive Reactions?			
Some persons may react to the TST even though	they are not infecte	ed with M. tuberculosis. The causes of	
these false-positive reactions may include, but ar	e not limited to, the	e following:	
Infection with nontuberculosis mycobacteria			
Previous BCG vaccination			
Incorrect method of TST administration			
Incorrect interpretation of reaction			
 Incorrect bottle of antigen used 			
What Are False-Negative Reactions?			
Some persons may not react to the TST even thou	ugh they are infecte	ed with M. tuberculosis. The reasons for	
these false-negative reactions may include, but a	re not limited to, th	e following:	
Cutaneous anergy (anergy is the inability to react	to skin tests becau	se of a weakened immune system)	
Recent TB infection (within 8-10 weeks of exposu	ire)		
Very old TB infection (many years)			
Very young age (less than 6 months old)			



ADVANCE DIAGNOSTICS CENTRE

C1-C2/17A, NEAR NIHARIKA TALKIES KORBA- 495677 PH-09228333 MOBILE-9300888178

NAME : MR MOHAN THAKUR

Ref. By : DR. BHATT NEELIMA

Address :

33 Years / Male

MaleReg No. : 20736Reg. Date: 21/08/2022 10:09AMCollected At: MedZone Center

INVESTIGATION REPORT

CLINICAL PATHOLOGY

<u>TEST</u>		<u>RESULT</u>	<u>UNIT</u>	TEST METHOD	
Recent live-virus vaccination (e.g., measles and smallpox) Overwhelming TB disease Some viral illnesses (e.g., measles and chicken pox) Incorrect method of TST administration Incorrect interpretation of reaction					
Sample Registered On Sample Received On	: 21/08/2022 10:09AM : 21/08/2022 10:11AM	End Of Rep 1	port	ani.	
Report Released On Sample Barcode :	: 24/08/2022 01:01PM	1 CI	necked By:tulesh	Dr. VANDANA CHANDANI	



Ref. By : DR. BHATT NEELIMA

Address :

33 Years / Male Reg No. : 20736

Reg. Date : 21/08/2022 10:09AM

Collected At : MedZone Center

INVESTIGATION REPORT

HAEMATOLOGY

TEST	<u>RESULT</u>	<u>UNIT</u>	BIOLOGICAL REF RANGE	TEST METHOD
CBP (Complete Blood Picture)				
Sample Type	: WB - EDTA			
Haemoglobin	: 12.5	gm%	12.0 - 18.0	
Total Erythrocyte Count	: 3.93	M/cmm	4.0 - 6.2	Cell Counter
Hemotocrit (PCV)	: 38.4	Vol %	35.0 - 50.0	
Mean Corpuscular Volume	: 97.7	fL	80 - 100	
Mean Corpuscular Hemoglobin	: 31.8	PG	26 - 34	
МСНС	: 32.6	g/L	31 - 35	
RDW	: 14.8	%	11.5 - 14.5	
Total Leucocyte Count.	: 5110	/cumm	4000 - 11000	
DIFFERENTIAL COUNT :				
Neutrophils	: 55	%	40 - 75	
Lymphocytes.	: 36	%	20 - 40	Cell Counter
Monocytes.	: 05	%	2 - 10	Cell Counter
Eosinophils	: 04	%	1 - 6	Cell Counter
Basophils	: 0	%	0 - 1	Cell Counter
Platelet Count	: 143000	/cmm	150000 - 450000	

ESR (Erythrocyte Sedimentation Rate)

Sample Type	: PLASMA -Na	Citrate		
ESR (Erythrocyte Sedimentation Rate)	: 25	mm/hr	0 - 15 :1st Hour	Sedimentation me

	-	End Of Report	
Sample Registered On	: 21/08/2022 10:09AM		1
Sample Received On	: 21/08/2022 10:11AM		Opri-
Report Released On	: 21/08/2022 02:58PM		Dr. VANDANA CHANDANI
Sample Barcode :		Checked By:tulesh	